Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

BRD4 facilitates replication stress-induced DNA damage response.

Zhang J, Dulak AM, Hattersley MM, Willis BS, Nikkilä J, Wang A, Lau A, Reimer C, Zinda M, Fawell SE, Mills GB, Chen H.

Oncogene. 2018 Jul;37(28):3763-3777. doi: 10.1038/s41388-018-0194-3. Epub 2018 Apr 11.

2.

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.

Rhyasen GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, Zhao W, Gharahdaghi F, Hattersley MM, Lyne PD, Clark E, Zinda M, Fawell SE, Mills GB, Chen H.

PLoS One. 2018 Jul 23;13(7):e0200826. doi: 10.1371/journal.pone.0200826. eCollection 2018.

3.

AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo.

Xu K, Chen D, Qian D, Zhang S, Zhang Y, Guo S, Ma Z, Wang S.

Biochem Biophys Res Commun. 2018 May 15;499(3):531-537. doi: 10.1016/j.bbrc.2018.03.184. Epub 2018 Mar 31.

PMID:
29596834
4.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.

Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, Dale IL, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh TC, Rabow AA, Dry JR, Reimer C, Lyne P, Mills GB, Fawell SE, Waring MJ, Zinda M, Clark E, Chen H.

Mol Cancer Ther. 2016 Nov;15(11):2563-2574. Epub 2016 Aug 29.

5.

AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.

Shen G, Chen J, Zhou Y, Wang Z, Ma Z, Xu C, Jiang M.

Cell Physiol Biochem. 2018;50(2):798-809. doi: 10.1159/000494244. Epub 2018 Oct 11.

6.

Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.

Kim HJ, Min A, Im SA, Jang H, Lee KH, Lau A, Lee M, Kim S, Yang Y, Kim J, Kim TY, Oh DY, Brown J, O'Connor MJ, Bang YJ.

Int J Cancer. 2017 Jan 1;140(1):109-119. doi: 10.1002/ijc.30373. Epub 2016 Oct 21.

7.

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.

Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.

8.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R.

Cancer Discov. 2018 Apr;8(4):458-477. doi: 10.1158/2159-8290.CD-17-0902. Epub 2018 Jan 31.

9.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC.

Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072.

10.

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors.

Yeh TC, O'Connor G, Petteruti P, Dulak A, Hattersley M, Barrett JC, Chen H.

Clin Cancer Res. 2017 Feb 15;23(4):1025-1035. doi: 10.1158/1078-0432.CCR-16-1658. Epub 2017 Jan 10.

11.

Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.

Xiang T, Bai JY, She C, Yu DJ, Zhou XZ, Zhao TL.

Cell Signal. 2018 Jan;42:106-113. doi: 10.1016/j.cellsig.2017.10.010. Epub 2017 Oct 16.

PMID:
29050985
12.

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.

Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer E, Letai A, Barry WT, Carroll JS, Long H, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K.

Nature. 2016 Jan 21;529(7586):413-417. doi: 10.1038/nature16508. Epub 2016 Jan 6.

13.

Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors.

Tripathi K, Mani C, Barnett R, Nalluri S, Bachaboina L, Rocconi RP, Athar M, Owen LB, Palle K.

J Biol Chem. 2014 Nov 7;289(45):31513-25. doi: 10.1074/jbc.M114.606483. Epub 2014 Sep 24.

14.

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.

Jin J, Fang H, Yang F, Ji W, Guan N, Sun Z, Shi Y, Zhou G, Guan X.

Neoplasia. 2018 May;20(5):478-488. doi: 10.1016/j.neo.2018.03.003. Epub 2018 Mar 30.

15.

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.

Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ.

Mol Cancer Ther. 2017 Jan;16(1):25-34. doi: 10.1158/1535-7163.MCT-16-0239. Epub 2016 Nov 9.

16.

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.

Min A, Im SA, Jang H, Kim S, Lee M, Kim DK, Yang Y, Kim HJ, Lee KH, Kim JW, Kim TY, Oh DY, Brown J, Lau A, O'Connor MJ, Bang YJ.

Mol Cancer Ther. 2017 Apr;16(4):566-577. doi: 10.1158/1535-7163.MCT-16-0378. Epub 2017 Jan 30.

17.

Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.

Sengupta D, Kannan A, Kern M, Moreno MA, Vural E, Stack B Jr, Suen JY, Tackett AJ, Gao L.

Epigenetics. 2015;10(6):460-6. doi: 10.1080/15592294.2015.1034416. Epub 2015 May 5.

18.

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.

Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.

19.

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.

Jones GN, Rooney C, Griffin N, Roudier M, Young LA, Garcia-Trinidad A, Hughes GD, Whiteaker JR, Wilson Z, Odedra R, Zhao L, Ivey RG, Howat WJ, Harrington EA, Barrett JC, Ramos-Montoya A, Lau A, Paulovich AG, Cadogan EB, Pierce AJ.

Br J Cancer. 2018 Nov;119(10):1233-1243. doi: 10.1038/s41416-018-0286-4. Epub 2018 Nov 2.

20.

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.

Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J, Shen L.

J Exp Clin Cancer Res. 2018 Jun 28;37(1):129. doi: 10.1186/s13046-018-0790-7.

Supplemental Content

Support Center